Pharmaceutics, Vol. 15, Pages 1109: Design and Evaluation of Dissolvable Microneedles for Treating Atopic Dermatitis

Pharmaceutics, Vol. 15, Pages 1109: Design and Evaluation of Dissolvable Microneedles for Treating Atopic Dermatitis

Pharmaceutics doi: 10.3390/pharmaceutics15041109

Authors: Noa Ben David Yuval Richtman Adi Gross Ruba Ibrahim Abraham Nyska Yuval Ramot Boaz Mizrahi

Atopic dermatitis (AD) is a chronic inflammatory skin disease caused predominantly by immune dysregulation. The global impact of AD continues to increase, making it not only a significant public health issue but also a risk factor for progression into other allergic phenotype disorders. Treatment of moderate-to-severe symptomatic AD involves general skin care, restoration of the skin barrier function, and local anti-inflammatory drug combinations, and may also require systemic therapy, which is often associated with severe adverse effects and is occasionally unsuitable for long-term use. The main objective of this study was to develop a new delivery system for AD treatment based on dissolvable microneedles containing dexamethasone incorporated in a dissolvable polyvinyl alcohol/polyvinylpyrrolidone matrix. SEM imaging of the microneedles showed well-structured arrays comprising pyramidal needles, fast drug release in vitro in Franz diffusion cells, an appropriate mechanical strength recorded with a texture analyzer, and low cytotoxicity. Significant clinical improvements, including in the dermatitis score, spleen weights, and clinical scores, were observed in an AD in vivo model using BALB/c nude mice. Taken together, our results support the hypothesis that microneedle devices loaded with dexamethasone have great potential as a treatment for AD and possibly for other skin conditions as well.